Peroxidasin Inhibition by Phloroglucinol and Other Peroxidase Inhibitors
Antioxidants · 21.12.2023 · 13 (1) · 23
DOI: 10.3390/antiox13010023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 21.12.2023. Verfasst von Martina Paumann-Page und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mātai Hāora Centre for Redox Biology and Medicine, University of Otago Christchurch, Ōtautahi Christchurch 8011, New Zealand. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marsden Fund of New Zealand, CMRF Canterbury Medical Research Foundation Project, FWF.
Abstract (Originalsprache)
Human peroxidasin (PXDN) is a ubiquitous peroxidase enzyme expressed in most tissues in the body. PXDN represents an interesting therapeutic target for inhibition, as it plays a role in numerous pathologies, including cardiovascular disease, cancer and fibrosis. Like other peroxidases, PXDN generates hypohalous acids and free radical species, thereby facilitating oxidative modifications of numerous biomolecules. We have studied the inhibition of PXDN halogenation and peroxidase activity by phloroglucinol and 14 other peroxidase inhibitors. Although a number of compounds on their own potently inhibited PXDN halogenation activity, only five were effective in the presence of a peroxidase substrate with IC50 values in the low μM range. Using sequential stopped-flow spectrophotometry, we examined the mechanisms of inhibition for several compounds. Phloroglucinol was the most potent inhibitor with a nanomolar IC50 for purified PXDN and IC50 values of 0.95 μM and 1.6 μM for the inhibition of hypobromous acid (HOBr)-mediated collagen IV cross-linking in a decellularized extracellular matrix and a cell culture model. Other compounds were less effective in these models. Most interestingly, phloroglucinol was identified to irreversibly inhibit PXDN, either by mechanism-based inhibition or tight binding. Our work has highlighted phloroglucinol as a promising lead compound for the design of highly specific PXDN inhibitors and the assays used in this study provide a suitable approach for high-throughput screening of PXDN inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mātai Hāora Centre for Redox Biology and Medicine, University of Otago Christchurch, Ōtautahi Christchurch 8011, New Zealand.
- Institute of Biochemistry, Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria.
ORCID-Profile: Christian Obinger, Christine C Winterbourn, Paul G Furtmüller
Förderung
- Marsden Fund of New Zealand
- CMRF Canterbury Medical Research Foundation Project
- FWF
Zitieren
APA
Paumann-Page, M., Obinger, C., Winterbourn, C. C., & Furtmüller, P. G. (2023). Peroxidasin Inhibition by Phloroglucinol and Other Peroxidase Inhibitors. Antioxidants, 13(1), 23. https://doi.org/10.3390/antiox13010023
Vancouver
Paumann-Page M, Obinger C, Winterbourn CC, Furtmüller PG. Peroxidasin Inhibition by Phloroglucinol and Other Peroxidase Inhibitors. Antioxidants. 2023;13(1):23. doi:10.3390/antiox13010023
BibTeX
@article{PaumannPage2023,
author = {Paumann-Page, Martina and Obinger, Christian and Winterbourn, Christine C and Furtmüller, Paul G},
title = {Peroxidasin Inhibition by Phloroglucinol and Other Peroxidase Inhibitors},
journal = {Antioxidants},
year = {2023},
volume = {13},
number = {1},
pages = {23},
doi = {10.3390/antiox13010023}
}
EUVIMED